[
    {
        "pregunta": "1. These questions cover diagnosis, classification, clinical features, management, and follow-up of Juvenile Idiopathic Arthritis based on current guideline principles.",
        "respuesta": "The provided information does not include specific details on the current guideline principles regarding the diagnosis, classification, clinical features, management, and follow-up of Juvenile Idiopathic Arthritis (JIA). Therefore, a reliable response on these topics cannot be given based on the available data.",
        "contexto": [
            "2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using",
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting",
            "JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "<h1>Table 2. Guiding principles for the integrative management of rheumatoid arthritis*</h1>"
        ]
    },
    {
        "pregunta": "2. ¿Cuál es el csDMARD preferido para la AIJ oligoarticular y por qué?",
        "respuesta": "Según la información proporcionada, para la artritis idiopática juvenil (AIJ) con actividad oligoarticular y respuesta inadecuada o intolerancia a AINEs y/o inyecciones intraarticulares de corticoides (IAGCs), se recomienda fuertemente el uso de DMARDs sintéticos convencionales (csDMARDs). Sin embargo, no se especifica un csDMARD preferido para la AIJ oligoarticular en particular.\n\nPor otro lado, en niños con AIJ y afectación de la articulación temporomandibular (TMJ), el metotrexato (MTX) es condicionalmente recomendado como agente preferido sobre leflunomida (LEF).\n\nEn resumen:\n\n- Para AIJ oligoarticular, no hay un csDMARD preferido claramente establecido en la información disponible.  \n- MTX es condicionalmente preferido sobre LEF en casos específicos (p. ej., AIJ con artritis TMJ).\n\nPor lo tanto, la información proporcionada no permite identificar un csDMARD preferido específico para la AIJ oligoarticular en general.",
        "contexto": [
            "in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active oligoarthritis. There is no preferred bDMARD. Biologic DMARDs are preferred over combining csDMARDs or switching to a different csDMARD, due to a greater likelihood that bDMARDs will yield rapid and sustained improvement in JIA Although tumor necrosis factor inhibitors (TNFi) are the",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "|Conventional synthetic DMARDs are strongly recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs.|Very low|PICO 15. In children with JIA with active TMJ arthritis, should DMARD therapies be recommended, and should there be any preferred order of treatment: MTX (subcutaneous and oral), LEF, SSZ, and/or HCQ?|58–59|\n|MTX is conditionally recommended as a preferred agent over LEF.| | | |",
            "|Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 conventional synthetic DMARD.|Very low|PICO 6. In children with oligoarticular JIA, should biologic therapies be recommended, and should there be any preferred order of treatment: TNFi treatment, biologic treatments with other mechanisms of action?|42–47|\n|There is no preferred biologic DMARD.| | | |",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>"
        ]
    },
    {
        "pregunta": "3. What is the role of calcineurin inhibitors in systemic JIA with MAS, and how do they compare to IL-1 or IL-6 inhibitors?",
        "respuesta": "En la artritis idiopática juvenil sistémica (AIJ sistémica) con síndrome de activación macrofágica (MAS), los inhibidores de la calcineurina se utilizan como parte del tratamiento, pero la recomendación es condicionalmente a favor de los inhibidores biológicos de IL-1 o IL-6 por sobre el uso exclusivo de inhibidores de la calcineurina para lograr enfermedad inactiva y resolución del MAS.\n\nEn resumen:\n\n- **Inhibidores de IL-1 o IL-6**: Condicionalmente recomendados sobre los inhibidores de la calcineurina solos para alcanzar inactividad de la enfermedad y resolución del MAS.  \n- **Inhibidores de la calcineurina**: Pueden usarse, pero se consideran menos efectivos que los inhibidores biológicos de IL-1 o IL-6 cuando se usan solos.  \n- No hay un agente biológico preferido específico entre IL-1 o IL-6.  \n- En caso de no respuesta o respuesta parcial a la terapia biológica, la incorporación de un inhibidor de la calcineurina ha sido evaluada, aunque la recomendación formal está diferida debido a la evidencia muy baja.\n\nPor tanto, los inhibidores de IL-1 o IL-6 tienen un rol más destacado y preferido condicionalmente frente a los inhibidores de la calcineurina solos en el manejo del MAS en AIJ sistémica.",
        "contexto": [
            "|IL-1 and IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS.|Very low|PICO 25. In patients with systemic JIA and overt MAS, is biologic therapy superior to calcineurin inhibitors for achievement of inactive disease and resolution of MAS?|131–136|\n|Glucocorticoids are conditionally recommended as part of initial treatment of systemic JIA with MAS. There is no preferred agent.| | | |",
            "long-term use of glucocorticoids Systemic JIA with MAS: initial therapy (Table 6 Infections can trigger MAS; therefore, all persons with MAS should be evaluated for infection concurrently with or prior to initiation of therapy Biologic DMARDs IL-1 or IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS for systemic JIA with MAS. There is no preferred agent. IL-1 and IL-6 inhibitors have proven to be very helpful in the",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "agent. IL-1 and IL-6 inhibitors have proven to be very helpful in the treatment of systemic JIA and MAS Glucocorticoids Glucocorticoids are conditionally recommended as part of initial treatment of systemic JIA with MAS. The benefits of glucocorticoids for MAS often outweigh their risks, even in patients whose MAS is triggered by infection. Systemic glucocorticoids may be necessary for severely ill patients because they can have a rapid onset of action. However, although treatment with",
            "|Formal recommendation deferred|Very low|PICO 26. For nonresponse or partial response to biologic therapy, is addition of a calcineurin inhibitor superior to etoposide or IVIG or plasmapheresis for achievement of inactive disease and resolution of MAS?|137–138|"
        ]
    },
    {
        "pregunta": "4. What are the potential long-term complications of untreated or poorly controlled JIA?",
        "respuesta": "La información proporcionada no incluye detalles específicos acerca de las posibles complicaciones a largo plazo de la artritis idiopática juvenil (AIJ) no tratada o mal controlada. Por lo tanto, no es posible ofrecer una respuesta confiable sobre este tema basándose en los datos disponibles.",
        "contexto": [
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "the recommendation is indirect and very low quality. The exceptions listed for the first recommendation above, including delay for personal reasons or other ongoing medical comorbidities, apply to this recommendation as well. Patients who have an acute flare of their OA or other inflammatory arthropathy (e.g., gout, calcium pyrophosphate deposition disease) may be interested in delaying TJA for treatment with a glucocorticoid injection to provide immediate pain relief. There are, however,",
            "JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians",
            "in JIA Although tumor necrosis factor inhibitors (TNFi) are the most commonly used bDMARDs in children Risk factors for poor prognosis and disease activity measures Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity"
        ]
    },
    {
        "pregunta": "5. ¿Cuál es la recomendación inicial para el tratamiento de la AIJ sistémica sin síndrome de activación macrofágica (MAS)?",
        "respuesta": "La recomendación inicial para el tratamiento de la artritis idiopática juvenil (AIJ) sistémica **sin síndrome de activación macrofágica (MAS)** es el uso de **biológicos inhibidores de IL-1 o IL-6 como monoterapia**, de manera condicional. \n\n- No hay un agente biológico preferido específico entre los inhibidores de IL-1 o IL-6.  \n- Estos tratamientos son altamente efectivos y bien tolerados, y se han adoptado rápidamente en la práctica clínica.\n\nPor lo tanto, el abordaje inicial condicionado para AIJ sistémica sin MAS es iniciar monoterapia con un inhibidor biológico de IL-1 o IL-6.",
        "contexto": [
            "bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 7. Systemic JIA with inactive disease*</h1>",
            "long-term use of glucocorticoids Systemic JIA with MAS: initial therapy (Table 6 Infections can trigger MAS; therefore, all persons with MAS should be evaluated for infection concurrently with or prior to initiation of therapy Biologic DMARDs IL-1 or IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS for systemic JIA with MAS. There is no preferred agent. IL-1 and IL-6 inhibitors have proven to be very helpful in the",
            "multiple small studies of systemic JIA that documented lack of efficacy at controlling systemic features that are typically present at onset of disease, leading to a continued need for glucocorticoids Systemic JIA without MAS: subsequent therapy (Table 5 IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of csDMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids for systemic JIA without MAS. Most physicians and patients/caregivers",
            "|IL-1 and IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS.|Very low|PICO 25. In patients with systemic JIA and overt MAS, is biologic therapy superior to calcineurin inhibitors for achievement of inactive disease and resolution of MAS?|131–136|\n|Glucocorticoids are conditionally recommended as part of initial treatment of systemic JIA with MAS. There is no preferred agent.| | | |"
        ]
    },
    {
        "pregunta": "6. How is systemic JIA characterized, and what are its key clinical features?",
        "respuesta": "La información proporcionada no incluye detalles específicos sobre la caracterización clínica ni las principales características de la artritis idiopática juvenil sistémica (AIJ sistémica). Por lo tanto, no es posible ofrecer una respuesta confiable sobre este tema basándose en los datos disponibles.",
        "contexto": [
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 7. Systemic JIA with inactive disease*</h1>",
            "<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 5. Systemic JIA without MAS*</h1>"
        ]
    },
    {
        "pregunta": "7. What laboratory tests are recommended for diagnosing JIA?",
        "respuesta": "La información proporcionada **no incluye detalles específicos sobre los análisis de laboratorio recomendados para el diagnóstico de la artritis idiopática juvenil (AIJ)**. Por lo tanto, no es posible ofrecer una respuesta confiable sobre este tema basándose en los datos disponibles.",
        "contexto": [
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>"
        ]
    },
    {
        "pregunta": "8. When should tapering and discontinuation of glucocorticoids be considered in systemic JIA?",
        "respuesta": "La reducción y suspensión de glucocorticoides en la artritis idiopática juvenil sistémica (AIJ sistémica) debe considerarse **una vez que se ha alcanzado la inactividad de la enfermedad**. \n\n- La pauta es realizar un **tapering (reducción gradual) y la suspensión de glucocorticoides** después de que la enfermedad esté inactiva, con una recomendación fuerte a favor de esta práctica basada en evidencia de muy baja certeza (PICO 28).  \n- Esto es para minimizar el riesgo de efectos adversos y toxicidad asociados al uso prolongado de glucocorticoides.  \n- El uso de glucocorticoides en AIJ sistémica debe ser limitado a la **dosis efectiva más baja y por el menor tiempo posible**, debido a los riesgos relacionados con la salud ósea, crecimiento y otros efectos secundarios.  \n\nEn resumen, se debe iniciar la reducción y suspensión de glucocorticoides tan pronto como la AIJ sistémica esté en remisión o inactiva, favoreciendo estrategias alternativas como bDMARDs frente a la terapia prolongada con glucocorticoides.",
        "contexto": [
            "<p>|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|\n|---|---|---|---|\n|Tapering and discontinuing glucocorticoids is strongly recommended after inactive disease has been attained.|Very low|PICO 28. In patients with systemic JIA with inactive disease treated with oral steroids, is taper to discontinuation of steroids superior to continuing long-term stable-dose steroids for preventing disease flare and minimizing side effects/medication toxicity?|139|",
            "|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|",
            "proportion of patients with systemic JIA will respond to NSAIDs alone Glucocorticoids Oral glucocorticoids are conditionally recommended against as initial monotherapy for systemic JIA without MAS. In most cases, oral glucocorticoids should not be used as initial monotherapy in patients with systemic JIA without MAS and, if used, should be limited to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately",
            "6 Biologic DMARDS or csDMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. Inactive systemic JIA with or without history of MAS (Table 7 Tapering and discontinuing glucocorticoids is strongly recommended after inactive disease has been attained in systemic JIA. The risk of flare from systemic JIA that is well controlled is considerably outweighed by possible harms from long-term glucocorticoid use, even at",
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making"
        ]
    },
    {
        "pregunta": "9. What factors contribute to the conditional nature of recommendations in the treatment of juvenile idiopathic arthritis?",
        "respuesta": "Las recomendaciones en el tratamiento de la artritis idiopática juvenil (AIJ) son condicionales debido a varios factores que afectan la certeza y aplicabilidad de la evidencia disponible. Según la información proporcionada, los principales factores que contribuyen a que las recomendaciones sean condicionales incluyen:\n\n- **Evidencia de muy baja certeza:** Muchas recomendaciones se basan en estudios con poca calidad metodológica o en evidencia limitada, lo que reduce la confianza en los beneficios y riesgos reportados.  \n- **Heterogeneidad clínica:** La variabilidad en la presentación clínica de la AIJ, incluyendo diferentes subtipos, articulaciones afectadas (por ejemplo, tobillo, muñeca, cadera, articulación temporomandibular), presencia o no de características pronósticas adversas, y enfermedades extraarticulares no consideradas en las guías, dificulta la generalización de los resultados.  \n- **Factores pronósticos inciertos:** La consideración de factores de mal pronóstico para guiar las decisiones terapéuticas está recomendada, pero la evidencia para modificar el tratamiento según estos factores es de muy baja certeza.  \n- **Ausencia de un agente preferido:** No existe un DMARD biológico preferido para determinados subtipos o situaciones, lo que indica que las decisiones deben individualizarse y pueden variar según el contexto clínico y disponibilidad.  \n- **Limitaciones en el diseño de estudios:** Falta de estudios grandes, controlados y bien diseñados específicos para subtipos de AIJ, especialmente en aspectos como pronóstico, combinaciones terapéuticas y resultados long-term.\n\nEn síntesis, las recomendaciones son condicionales principalmente por la limitada calidad y cantidad de evidencia específica, la heterogeneidad de la enfermedad y la necesidad de individualizar el tratamiento según factores clínicos y pronósticos variables.",
        "contexto": [
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making",
            "JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "in JIA Although tumor necrosis factor inhibitors (TNFi) are the most commonly used bDMARDs in children Risk factors for poor prognosis and disease activity measures Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity"
        ]
    },
    {
        "pregunta": "10. What is the typical age of onset for Juvenile Idiopathic Arthritis?",
        "respuesta": "La información proporcionada no incluye datos específicos sobre la edad típica de inicio de la artritis idiopática juvenil (AIJ). Por lo tanto, no es posible ofrecer una respuesta confiable basada en los datos disponibles.",
        "contexto": [
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "<h1>Table 2. Strength of recommendations and quality of supporting evidence*</h1>\n\n<p>|Condition|No. of recommendations|Conditional|Strong|Very low|Low|Moderate|High|\n|---|---|---|---|---|---|---|---|\n|Oligoarthritis|9|5|4|7|2|0|0|\n|TMJ arthritis|7|6|1|7|0|0|0|\n|Systemic JIA|9|5|4|9|0|0|0|\n|Total|25|16|9|23|2|0|0|</p>\n\n<ul>\n<li>TMJ = temporomandibular joint; JIA = juvenile idiopathic arthritis.</li>\n</ul>\n\n<h1>Table 3. Oligoarticular JIA*</h1>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>"
        ]
    },
    {
        "pregunta": "11. ¿Cuáles son las recomendaciones específicas para el manejo de la artritis activa de la articulación temporomandibular (ATM) en la AIJ?",
        "respuesta": "Las recomendaciones específicas para el manejo de la artritis activa de la articulación temporomandibular (ATM) en la artritis idiopática juvenil (AIJ), según la información disponible, son las siguientes:\n\n- Se recomienda de manera condicional un **ensayo breve de antiinflamatorios no esteroideos (AINEs)** como parte de la terapia inicial para la artritis activa de ATM. Este ensayo debe ser breve debido a posibles efectos adversos (p. ej., gastritis, moretones).\n- Se recomienda de manera condicional el uso de **inyecciones intraarticulares de glucocorticoides (IAGCs)** como parte de la terapia inicial.\n- Se recomienda de manera condicional **no usar glucocorticoides orales** como parte de la terapia inicial para la artritis activa de ATM.\n- No existe un agente biológico preferido para el tratamiento específico de la artritis activa de ATM.\n- Se aconseja considerar factores de mal pronóstico (por ejemplo, afectación de tobillo, muñeca, cadera, articulación sacroilíaca y/o ATM, presencia de enfermedad erosiva, entesitis, retraso en el diagnóstico, niveles elevados de marcadores inflamatorios, enfermedad simétrica) para guiar decisiones terapéuticas, aunque esta recomendación es de evidencia muy baja.\n\nEn resumen, el manejo inicial de la artritis activa de la ATM en AIJ incluye un corto curso de AINEs, la consideración de IAGCs intraarticulares, y se desaconseja el uso de glucocorticoides orales, todo en el contexto de una recomendación condicional basada en evidencia de baja certeza.",
        "contexto": [
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting",
            "are several validated disease activity measures for childhood arthritis Treat-to-target approaches have been strongly endorsed for polyarticular JIA Active TMJ arthritis (Figure 2 4 NSAIDs A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy for active TMJ arthritis. NSAIDs have long been the cornerstone of treatment for JIA and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "|IAGCs are conditionally recommended as part of initial therapy.|Very low|PICO 12. In children with JIA with active TMJ arthritis, should adding intraarticular glucocorticoids to initial therapy be recommended?|53–57|\n|There is no preferred agent.|Very low|PICO 14. In children with JIA with active TMJ arthritis, should a specific steroid type be recommended for intraarticular injection?|58|",
            "|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|"
        ]
    },
    {
        "pregunta": "12. ¿Cuándo se considera el uso de bDMARDs en la artritis activa de la ATM?",
        "respuesta": "El uso de **biológicos (bDMARDs)** en el tratamiento de la artritis activa de la articulación temporomandibular (ATM) en la artritis idiopática juvenil (AIJ) se considera **de manera condicional** en los siguientes casos:\n\n- Cuando hay **respuesta inadecuada o intolerancia a antiinflamatorios no esteroideos (AINEs) y/o inyecciones intraarticulares de glucocorticoides (IAGCs)** y al menos a un DMARD sintético convencional (csDMARD).  \n- En estas situaciones, la recomendación es iniciar terapia con bDMARDs para controlar la artritis activa de ATM.\n\nNo existe un bDMARD preferido para el tratamiento específico de la artritis activa de ATM, debido a que los estudios realizados han sido pequeños y observacionales, limitando la determinación de un orden preferido de agentes biológicos (p. ej., inhibidores de TNF u otros).\n\nEn resumen, los bDMARDs se consideran cuando falla el tratamiento inicial con AINEs, IAGCs y csDMARD, y deben individualizarse según la respuesta clínica y la tolerancia del paciente.",
        "contexto": [
            "in JIA Although tumor necrosis factor inhibitors (TNFi) are the most commonly used bDMARDs in children Risk factors for poor prognosis and disease activity measures Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity",
            "due to major impact on activities of daily living, and thus, early use of csDMARD therapy is encouraged. The limited available evidence supports the use of methotrexate Biologic DMARDs Biologic DMARDs are conditionally recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active TMJ arthritis. There is no preferred bDMARD. Voting panelists deferred recommending a specific bDMARD because current studies of TMJ arthritis have been small and",
            "bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "|MTX is conditionally recommended as a preferred agent over LEF.| | | |\n|Biologic DMARDs are conditionally recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 conventional synthetic DMARD.|Very low|PICO 16. In children with JIA with active TMJ arthritis, should systemic biologic therapies be recommended, and should there be any preferred order of treatment: TNFi, biologic treatments with other mechanisms of action?|59|"
        ]
    },
    {
        "pregunta": "13. What is the role of antinuclear antibodies (ANA) in the evaluation of JIA patients?",
        "respuesta": "La información proporcionada no incluye detalles específicos sobre el papel de los anticuerpos antinucleares (ANA) en la evaluación de pacientes con artritis idiopática juvenil (AIJ). Por lo tanto, no es posible ofrecer una respuesta confiable sobre este tema basándose en los datos disponibles.",
        "contexto": [
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis  unknown      A7FDDF976624E2E85584FDD8C00804F0 10.1002/acr.24634  INTRODUCTION The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) comprise granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These diseases affect smalland medium-sized vessels",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 7. Systemic JIA with inactive disease*</h1>"
        ]
    },
    {
        "pregunta": "14. ¿Por qué se recomienda evitar el uso de glucocorticoides orales como monoterapia inicial en AIJ sistémica sin MAS?",
        "respuesta": "Se recomienda evitar el uso de **glucocorticoides orales como monoterapia inicial en la artritis idiopática juvenil (AIJ) sistémica sin síndrome de activación macrofágica (MAS)** porque esta práctica tiene una recomendación condicional en contra basada en evidencia de muy baja certeza. \n\nLas razones principales incluyen:\n\n- Los glucocorticoides orales como monoterapia inicial no controlan adecuadamente las manifestaciones sistémicas ni la actividad inflamatoria de la AIJ sistémica sin MAS.  \n- El uso prolongado o frecuente de glucocorticoides orales se asocia con posibles efectos adversos importantes, incluyendo toxicidad, impacto negativo en crecimiento, salud ósea y otros efectos secundarios.  \n- Los inhibidores biológicos de IL-1 o IL-6 son considerados terapias iniciales preferidas y más efectivas para esta forma de AIJ, con mejor balance entre eficacia y seguridad.  \n- Si se usan glucocorticoides orales, deben mantenerse en la dosis efectiva más baja y por el menor tiempo posible, y siempre asociados a estrategias de reducción y suspensión una vez que se logre inactividad de la enfermedad.\n\nEn resumen, el evitar glucocorticoides orales como monoterapia inicial se fundamenta en la baja eficacia para controlar la enfermedad sistémica y en la intención de minimizar riesgos asociados a su uso prolongado, favoreciendo en cambio el inicio precoz de bDMARDs como inhibidores de IL-1 o IL-6.",
        "contexto": [
            "proportion of patients with systemic JIA will respond to NSAIDs alone Glucocorticoids Oral glucocorticoids are conditionally recommended against as initial monotherapy for systemic JIA without MAS. In most cases, oral glucocorticoids should not be used as initial monotherapy in patients with systemic JIA without MAS and, if used, should be limited to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately",
            "|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|",
            "long-term use of glucocorticoids Systemic JIA with MAS: initial therapy (Table 6 Infections can trigger MAS; therefore, all persons with MAS should be evaluated for infection concurrently with or prior to initiation of therapy Biologic DMARDs IL-1 or IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS for systemic JIA with MAS. There is no preferred agent. IL-1 and IL-6 inhibitors have proven to be very helpful in the",
            "6 Biologic DMARDS or csDMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. Inactive systemic JIA with or without history of MAS (Table 7 Tapering and discontinuing glucocorticoids is strongly recommended after inactive disease has been attained in systemic JIA. The risk of flare from systemic JIA that is well controlled is considerably outweighed by possible harms from long-term glucocorticoid use, even at",
            "multiple small studies of systemic JIA that documented lack of efficacy at controlling systemic features that are typically present at onset of disease, leading to a continued need for glucocorticoids Systemic JIA without MAS: subsequent therapy (Table 5 IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of csDMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids for systemic JIA without MAS. Most physicians and patients/caregivers"
        ]
    },
    {
        "pregunta": "15. What non-pharmacologic interventions are recommended for children with JIA?",
        "respuesta": "La información proporcionada **no incluye detalles específicos sobre intervenciones no farmacológicas recomendadas para niños con artritis idiopática juvenil (AIJ)**. Por lo tanto, no es posible ofrecer una respuesta confiable sobre este tema basándose en los datos disponibles.",
        "contexto": [
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|",
            "|IAGCs are conditionally recommended as part of initial therapy.|Very low|PICO 12. In children with JIA with active TMJ arthritis, should adding intraarticular glucocorticoids to initial therapy be recommended?|53–57|\n|There is no preferred agent.|Very low|PICO 14. In children with JIA with active TMJ arthritis, should a specific steroid type be recommended for intraarticular injection?|58|"
        ]
    },
    {
        "pregunta": "16. When should disease-modifying antirheumatic drugs (DMARDs) be initiated in JIA management?",
        "respuesta": "La información proporcionada no ofrece una recomendación específica y general sobre el momento exacto para iniciar los medicamentos modificadores de la enfermedad (DMARDs) en la artritis idiopática juvenil (AIJ) en términos globales.\n\nSin embargo, según los datos disponibles para subtipos específicos:\n\n- En **AIJ sistémica sin síndrome de activación macrofágica (MAS)**, se recomienda **condicionalmente iniciar monoterapia con biológicos inhibidores de IL-1 o IL-6** como tratamiento inicial; por el contrario, se **desaconseja fuertemente el uso de DMARDs sintéticos convencionales (csDMARDs) como monoterapia inicial**.  \n- En AIJ oligoarticular con respuesta inadecuada o intolerancia a AINEs y/o inyecciones intraarticulares, el uso de csDMARDs está recomendado (sin especificar un agente preferido).  \n- En la artritis activa de la articulación temporomandibular (ATM), se recomienda considerar los bDMARDs condicionalmente **tras fallo o intolerancia a AINEs, inyecciones intraarticulares de glucocorticoides y al menos un csDMARD**.\n\nEn resumen, el inicio de DMARDs en AIJ se individualiza según el subtipo y la respuesta inicial, siendo fuertemente preferible iniciar bDMARDs (IL-1 o IL-6) en AIJ sistémica sin MAS, mientras que en otros subtipos se considera iniciar csDMARDs tras no respuesta a terapias iniciales no inmunosupresoras.\n\nNo se dispone de información suficiente para una recomendación general sobre el inicio de DMARDs para todos los tipos de AIJ.",
        "contexto": [
            "|Conventional synthetic DMARDs are strongly recommended against as initial monotherapy.|Very low|PICO 21. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should DMARD treatment (MTX, calcineurin inhibitor) be used as initial therapy, and is there a preferred order?|67–68|",
            "recommendation is conditional, as bDMARDs may not always be immediately available, and glucocorticoids may help control systemic and joint manifestations until IL-1 or IL-6 inhibitors can be started. Conventional synthetic DMARDs Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA without MAS. This recommendation is strong despite limited evidence, as the Voting Panel noted multiple small studies of systemic JIA that documented lack of efficacy",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "|Biologic DMARDs (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy.|Very low|PICO 22. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should biologic treatment (anakinra, canakinumab, tocilizumab, or others) be used as initial therapy, and is there a preferred order?|69–71|\n|There is no preferred agent.| | | |"
        ]
    },
    {
        "pregunta": "17. ¿Cuáles son los riesgos asociados con el uso de glucocorticoides orales en el manejo inicial de la AIJ?",
        "respuesta": "Los riesgos asociados con el uso de glucocorticoides orales en el manejo inicial de la artritis idiopática juvenil (AIJ) incluyen:\n\n- Efectos adversos importantes relacionados con el crecimiento y la salud ósea, como osteoporosis y posible impacto negativo en el desarrollo óseo.  \n- Mayor riesgo de infecciones.  \n- Riesgo aumentado de complicaciones cardiovasculares a largo plazo.  \n- Dificultad frecuente para realizar un correcto descenso (tapering) que puede llevar a un uso prolongado e indeseado.  \n- Toxicidad asociada al uso prolongado de glucocorticoides en la infancia.\n\nPor estas razones, el uso de glucocorticoides orales como monoterapia inicial en AIJ está recomendado en contra de manera condicional, y si se usan, deben mantenerse a la dosis más baja efectiva y por el menor tiempo posible.",
        "contexto": [
            "|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|",
            "proportion of patients with systemic JIA will respond to NSAIDs alone Glucocorticoids Oral glucocorticoids are conditionally recommended against as initial monotherapy for systemic JIA without MAS. In most cases, oral glucocorticoids should not be used as initial monotherapy in patients with systemic JIA without MAS and, if used, should be limited to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately",
            "|IAGCs are conditionally recommended as part of initial therapy.|Very low|PICO 12. In children with JIA with active TMJ arthritis, should adding intraarticular glucocorticoids to initial therapy be recommended?|53–57|\n|There is no preferred agent.|Very low|PICO 14. In children with JIA with active TMJ arthritis, should a specific steroid type be recommended for intraarticular injection?|58|",
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making",
            "update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2"
        ]
    },
    {
        "pregunta": "18. How is disease activity monitored in patients with JIA?",
        "respuesta": "La monitorización de la actividad de la enfermedad en pacientes con artritis idiopática juvenil (AIJ) se realiza mediante la **utilización de medidas validadas de actividad de la enfermedad**, que están condicionadamente recomendadas para guiar las decisiones terapéuticas y facilitar un enfoque de tratamiento dirigido a objetivos (treat-to-target).\n\nAspectos clave:\n\n- Se recomienda el uso formal y sistemático de escalas o instrumentos validados específicos para evaluar la actividad de la enfermedad en AIJ.  \n- Estas medidas permiten modificar el tratamiento de forma objetiva, especialmente en subtipos como la oligoartritis, y considerar características clínicas como la afectación de articulaciones específicas (por ejemplo, tobillo, muñeca, cadera, articulación temporomandibular).  \n- La inclusión de factores de riesgo de mal pronóstico (presencia de artritis erosiva, entesitis, retraso en el diagnóstico, simbología inflamatoria elevada, enfermedad simétrica) también es condicionalmente recomendada para orientar las decisiones clínicas en conjunto con las medidas de actividad.  \n- Existen varias herramientas validadas para evaluar la actividad en la AIJ, aunque no se especifican en el dato disponible.\n\nEn resumen, la monitorización se basa en evaluaciones formales con instrumentos validados de actividad de la enfermedad, aplicadas regularmente para ajustar el tratamiento según la respuesta y favorecer mejores resultados clínicos.",
        "contexto": [
            "|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "in JIA Although tumor necrosis factor inhibitors (TNFi) are the most commonly used bDMARDs in children Risk factors for poor prognosis and disease activity measures Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity",
            "to guide treatment decisions. Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches. Treatment for oligoarthritis can and should be modified based on the involvement of specific joints or disease features Voting panelists conditionally recommended formal assessment of disease activity using validated measures. There are several validated disease activity measures for childhood arthritis",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 7. Systemic JIA with inactive disease*</h1>"
        ]
    },
    {
        "pregunta": "19. ¿Qué inhibidores biológicos son recomendados para el tratamiento inicial de la AIJ sistémica sin MAS?",
        "respuesta": "Para el tratamiento inicial de la artritis idiopática juvenil (AIJ) sistémica **sin síndrome de activación macrofágica (MAS)**, se recomiendan **condicionalmente inhibidores biológicos de IL-1 o IL-6 como monoterapia**. \n\n- No existe un agente biológico preferido específico entre los inhibidores de IL-1 o IL-6.  \n- Estos tratamientos son altamente efectivos y bien tolerados, y se han adoptado rápidamente en la práctica clínica.\n\nPor lo tanto, la recomendación es iniciar tratamiento con un inhibidor biológico de IL-1 (p. ej., anakinra, canakinumab) o de IL-6 (p. ej., tocilizumab) de forma condicional como terapia inicial en AIJ sistémica sin MAS.",
        "contexto": [
            "|IL-1 and IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS.|Very low|PICO 25. In patients with systemic JIA and overt MAS, is biologic therapy superior to calcineurin inhibitors for achievement of inactive disease and resolution of MAS?|131–136|\n|Glucocorticoids are conditionally recommended as part of initial treatment of systemic JIA with MAS. There is no preferred agent.| | | |",
            "|Biologic DMARDs (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy.|Very low|PICO 22. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should biologic treatment (anakinra, canakinumab, tocilizumab, or others) be used as initial therapy, and is there a preferred order?|69–71|\n|There is no preferred agent.| | | |",
            "long-term use of glucocorticoids Systemic JIA with MAS: initial therapy (Table 6 Infections can trigger MAS; therefore, all persons with MAS should be evaluated for infection concurrently with or prior to initiation of therapy Biologic DMARDs IL-1 or IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS for systemic JIA with MAS. There is no preferred agent. IL-1 and IL-6 inhibitors have proven to be very helpful in the",
            "|There is no preferred agent.| | | |\n|IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of conventional synthetic DMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids.|Very low|PICO 23. In patients with systemic JIA without MAS who do not respond to initial therapy with nonbiologic treatments (NSAIDs, glucocorticoids, DMARDs), should nonbiologic treatments be combined or biologic treatment started?|72–130|",
            "bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice"
        ]
    },
    {
        "pregunta": "20. ¿Por qué se prefieren los bDMARDs sobre la combinación o cambio entre csDMARDs en la AIJ oligoarticular?",
        "respuesta": "Los fármacos modificadores de la enfermedad biológicos (bDMARDs) se prefieren sobre la combinación o el cambio entre modificadores sintéticos convencionales de la enfermedad (csDMARDs) en la artritis idiopática juvenil (AIJ) oligoarticular porque los bDMARDs tienen una mayor probabilidad de producir una mejoría rápida y sostenida. \n\nEspecíficamente:\n\n- En niños con AIJ oligoarticular que presentan respuesta inadecuada o intolerancia a antiinflamatorios no esteroideos (AINEs) y/o inyecciones intraarticulares de glucocorticoides (IAGCs) y al menos un csDMARD, se recomienda fuertemente el uso de bDMARDs.  \n- No existe un bDMARD preferido en particular, pero se considera que la terapia biológica es más eficaz para inducir y mantener la mejoría clínica.  \n- Se prefiere el uso de bDMARDs en lugar de combinar o cambiar entre csDMARDs debido a esta mayor eficacia potencial.\n\nEsta recomendación está basada en evidencia de muy baja certeza, pero refleja la práctica clínica actual para optimizar resultados en AIJ oligoarticular.",
        "contexto": [
            "in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active oligoarthritis. There is no preferred bDMARD. Biologic DMARDs are preferred over combining csDMARDs or switching to a different csDMARD, due to a greater likelihood that bDMARDs will yield rapid and sustained improvement in JIA Although tumor necrosis factor inhibitors (TNFi) are the",
            "|Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 conventional synthetic DMARD.|Very low|PICO 6. In children with oligoarticular JIA, should biologic therapies be recommended, and should there be any preferred order of treatment: TNFi treatment, biologic treatments with other mechanisms of action?|42–47|\n|There is no preferred biologic DMARD.| | | |",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or",
            "bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice"
        ]
    }
]